구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PVSRIPO (Polio/Rhinovirus Recombinant, Polio/Rhinovirus Recombinant (PVSRIPO)) Istari Oncology, Inc.·Malignant Glioma 12 trials |
|---|---|
Overview Program | Polio/Rhinovirus Recombinant (PVSRIPO) |
Overview Company | Istari Oncology, Inc. |
Overview Modality | CGT |
Overview Target | Malignant Glioma |
Overview Indication | Malignant Glioma; Anaplastic Astrocytoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles.. The poor prognosis of glioma underscores the urgent need for novel therapies. Recent advances in immunotherapy, especially in oncolytic virus therapy (OVT), have shown promising progress. In clinical trials, OVT has improved median overall survival up to 28.8 months. Different oncolytic viruses, including he… |
Clinical Safety signal | Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles.. The poor prognosis of glioma underscores the urgent need for novel therapies. Recent advances in immunotherapy, especially in oncolytic virus therapy (OVT), have shown promising progress. In clinical trials, OVT has improved median overall survival up to 28.8 months. Different oncolytic viruses, including he… |
Clinical Reported ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT03712358 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03712358 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PVSRIPO (Polio/Rhinovirus Recombinant, Polio/Rhinovirus Recombinant (PVSRIPO)) Istari Oncology, Inc.·Malignant Glioma 12 trials |
|---|---|
Overview Program | Polio/Rhinovirus Recombinant (PVSRIPO) |
Overview Company | Istari Oncology, Inc. |
Overview Modality | CGT |
Overview Target | Malignant Glioma |
Overview Indication | Malignant Glioma; Anaplastic Astrocytoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles.. The poor prognosis of glioma underscores the urgent need for novel therapies. Recent advances in immunotherapy, especially in oncolytic virus therapy (OVT), have shown promising progress. In clinical trials, OVT has improved median overall survival up to 28.8 months. Different oncolytic viruses, including he… |
Clinical Safety signal | Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles.. The poor prognosis of glioma underscores the urgent need for novel therapies. Recent advances in immunotherapy, especially in oncolytic virus therapy (OVT), have shown promising progress. In clinical trials, OVT has improved median overall survival up to 28.8 months. Different oncolytic viruses, including he… |
Clinical Reported ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT03712358 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03712358 |
추천 비교
추천 비교